(Q35075064)

6 August 2017

title

Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease (English)

1 reference

6 August 2017

0 references

Sridevi Devaraj

1

1 reference

6 August 2017

Catherine Duncan-Staley

series ordinal

2

1 reference

6 August 2017

Ishwarlal Jialal

series ordinal

3

1 reference

6 August 2017

publication date

13 August 2010

1 reference

Metabolic syndrome and related disorders

6 August 2017

published in

1 reference

6 August 2017

volume

8

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

477-482

1 reference

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125567

Structural and biochemical properties of fibroblast growth factor 23.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125567

Role of fibroblast growth factor 23 in health and in chronic kidney disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125567

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125567

Determination of fibroblast growth factor 23.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125567

Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125567

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125567

FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125567

Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3125567

Comparison of two assays for fibroblast growth factor (FGF)-23

27 September 2018

1 reference

12 December 2020

As nature did not predict dialysis--what we can learn from FGF23 in end-stage renal disease?

1 reference

12 December 2020

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

1 reference

12 December 2020

Overweight, obesity and chronic kidney disease

1 reference

12 December 2020

Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice

1 reference

12 December 2020

Identifiers

DOI

10.1089/MET.2010.0030

1 reference

6 August 2017

1 reference

6 August 2017

1 reference